Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 1
1 source rowRow 1 · 2026-10-06 · Disposition to issuer · Disposed 26,857 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 9, 2026 01:59 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Disposition to issuerCommon Stock | 26,857 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-418325 · ownership.xml · nonDerivative · entry 1 DuRoss Amy · CIK 0001854968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:56 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 8,170 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-012480 · wk-form4_1772146569.xml · nonDerivative · entry 1 DuRoss Amy · CIK 0001854968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,857 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan and fully vests on the first anniversary of the vesting date of January 2, 2026 Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 22:25 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 2,000 | $24.60 | $49,200.00 |
DisclosureSEC source: 0001628280-25-057721 · wk-form4_1766010355.xml · nonDerivative · entry 1 DuRoss Amy · CIK 0001854968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,687 Read SEC document |
| November 26, 2025 Filed Nov 28, 2025 22:39 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 2,000 | $27.00 | $54,000.00 |
DisclosureSEC source: 0001628280-25-054285 · wk-form4_1764369543.xml · nonDerivative · entry 2 DuRoss Amy · CIK 0001854968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,687 Read SEC document |
| November 25, 2025 Filed Nov 28, 2025 22:39 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 2,000 | $27.00 | $54,000.00 |
DisclosureSEC source: 0001628280-25-054285 · wk-form4_1764369543.xml · nonDerivative · entry 1 DuRoss Amy · CIK 0001854968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,687 Read SEC document |
| November 21, 2025 Filed Nov 21, 2025 23:34 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,000 | $26.00 | $26,000.00 |
DisclosureSEC source: 0001628280-25-053665 · wk-form4_1763768095.xml · nonDerivative · entry 3 DuRoss Amy · CIK 0001854968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,687 Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 23:34 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 4,523 | $24.51 | $110,858.73 |
DisclosureSEC source: 0001628280-25-053665 · wk-form4_1763768095.xml · nonDerivative · entry 2 DuRoss Amy · CIK 0001854968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,687 Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 23:34 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 477 | $24.50 | $11,686.50 |
DisclosureSEC source: 0001628280-25-053665 · wk-form4_1763768095.xml · nonDerivative · entry 1 DuRoss Amy · CIK 0001854968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,210 Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 23:09 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 6,876 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-014192 · wk-form4_1742512170.xml · nonDerivative · entry 2 DuRoss Amy · CIK 0001854968 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,687 F3 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the measurement date of 01-02-2025. Read SEC document |
| March 14, 2025 Filed Mar 20, 2025 23:09 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 5,632 | $24.96 | $140,574.72 |
DisclosureSEC source: 0001628280-25-014192 · wk-form4_1742512170.xml · nonDerivative · entry 1 DuRoss Amy · CIK 0001854968 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,811 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 12-13-2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.18 to $25.91, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 13, 2024 Filed Mar 13, 2024 22:37 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 5,065 | $17.00 | $86,105.00 |
DisclosureSEC source: 0001628280-24-011026 · wk-form4_1710369455.xml · nonDerivative · entry 3 DuRoss Amy · CIK 0001854968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,443 Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 22:37 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,135 | $16.86 | $103,436.10 |
DisclosureSEC source: 0001628280-24-011026 · wk-form4_1710369455.xml · nonDerivative · entry 2 DuRoss Amy · CIK 0001854968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,508 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.60 to $17.11, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 22:37 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 11,264 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-011026 · wk-form4_1710369455.xml · nonDerivative · entry 1 DuRoss Amy · CIK 0001854968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,643 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the grant date. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 21:09 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 598 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-036779 · wk-form4_1699045788.xml · nonDerivative · entry 1 DuRoss Amy · CIK 0001854968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,379 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash director fees at the last closing price as of the date of grant. Read SEC document |
| October 01, 2023 Filed Oct 10, 2023 21:27 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 437 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-034209 · wk-form4_1696973241.xml · nonDerivative · entry 1 DuRoss Amy · CIK 0001854968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,781 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash director fees at the last closing price as of the date of grant. Read SEC document |
| January 03, 2023 Filed Jan 19, 2023 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 10,187 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-001268 · rdgdoc.xml · nonDerivative · entry 1 DuRoss Amy · CIK 0001854968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,344 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and fully vests on the first anniversary of the grant date. Read SEC document |
| November 15, 2022 Filed Nov 18, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 2,600 | $24.35 | $63,310.00 |
DisclosureSEC source: 0001437749-22-027684 · rdgdoc.xml · nonDerivative · entry 1 DuRoss Amy · CIK 0001854968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,157 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.31 to $24.39, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 295 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-018516 · rdgdoc.xml · nonDerivative · entry 1 DuRoss Amy · CIK 0001854968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,757 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of directors fees at the last closing price as of the date of grant Read SEC document |
| July 01, 2022 Filed Jul 7, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 389 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-016764 · rdgdoc.xml · nonDerivative · entry 1 DuRoss Amy · CIK 0001854968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,462 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of directors fees at the last closing price as of the date of grant. Read SEC document |
| June 01, 2022 Filed Jun 4, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 343 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-014306 · rdgdoc.xml · nonDerivative · entry 1 DuRoss Amy · CIK 0001854968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,073 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of directors fees at the last closing price as of the date of grant. Read SEC document |
| May 06, 2022 Filed May 11, 2022 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 14,730 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-011804 · rdgdoc.xml · nonDerivative · entry 1 DuRoss Amy · CIK 0001854968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,730 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and fully vests on the first anniversary of the grant date. Read SEC document |
| April 12, 2021 Filed Apr 15, 2021 01:38 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-008952 · rdgdoc.xml · nonDerivative · entry 1 DuRoss Amy · CIK 0001854968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: The restricted stock award was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and fully vests on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.